Fosfomycin
Fosfomycin is a broad-spectrum antibiotic primarily used to treat uncomplicated urinary tract infections (UTIs) in women. It works by inhibiting bacterial cell wall synthesis and is often given as a single-dose regimen, making it a convenient option for certain infections. This medication is available in oral and intravenous formulations depending on the clinical indication.
Fosfomycin is an antibiotic used mainly for treating uncomplicated urinary tract infections, often as a single-dose treatment.
Key facts at a glance
- ATC
- J01XX01
- RxNorm
- 4550
- Generic
- Fosfomycin
- Class
- atc-j01
- Brands
- Contepo
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- solution, injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Fosfomycin is primarily indicated for uncomplicated urinary tract infections (cystitis) in women. It may also be used for complicated UTIs, pyelonephritis, and as prophylaxis for certain urological procedures. The oral formulation is particularly useful when treating infections caused by multi-drug resistant bacteria.
Fosfomycin exerts its antibacterial effect by inhibiting the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which is essential for the first step of bacterial cell wall synthesis (peptidoglycan formation). This bactericidal action prevents bacteria from forming cell walls, leading to bacterial death. Its unique mechanism means there is minimal cross-resistance with other antibiotic classes.
Fosfomycin is typically administered as a single 3-gram oral dose for uncomplicated UTIs. Common side effects include diarrhea, nausea, and headache. It is generally well-tolerated but should be used with caution in patients with severe renal impairment. Resistance to fosfomycin, while still uncommon, has been reported and is primarily associated with mutations in the murA gene or reduced drug uptake.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy